{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T02:43:53Z","timestamp":1775529833824,"version":"3.50.1"},"reference-count":14,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T00:00:00Z","timestamp":1304899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Vaccine\u2010induced p53\u2010specific immune responses were previously reported to be associated with improved response to secondary chemotherapy in patients with small cell lung cancer. We investigated long\u2010term clinical and immunological effects of the p53\u2010synthetic long peptide (p53\u2010SLP\u00ae) vaccine in patients with recurrent ovarian cancer. Twenty patients were immunized with the p53\u2010SLP\u00ae vaccine between July 2006 and August 2007. Follow\u2010up information on patients was obtained. Clinical responses to secondary chemotherapy after p53\u2010SLP\u00ae immunizations were determined by computerized tomography and\/or tumor marker levels (CA125). Disease\u2010specific survival was compared to a matched historical control group. Immune responses were analyzed by flow cytometry, proliferation assay, interferon gamma (IFN\u2010\u03b3) ELISPOT and\/or cytokine bead array. Lymphocytes cultured from skin biopsy were analyzed by flow cytometry and proliferation assay. Of 20 patients treated with the p53\u2010SLP\u00ae vaccine, 17 were subsequently treated with chemotherapy. Eight of these patients volunteered another blood sample. No differences in clinical response rates to secondary chemotherapy or disease\u2010specific survival were observed between immunized patients and historical controls (<jats:italic>p<\/jats:italic> = 0.925, resp. <jats:italic>p<\/jats:italic> = 0.601). p53\u2010specific proliferative responses were observed in 5\/8 patients and IFN\u2010\u03b3 production in 2\/7 patients. Lymphocytes cultured from a prior injection site showing inflammation during chemotherapy did not recognize p53\u2010SLP\u00ae. Thus, treatment with the p53\u2010SLP\u00ae vaccine does not affect responses to secondary chemotherapy or survival, although p53\u2010specific T\u2010cells do survive chemotherapy.<\/jats:p>","DOI":"10.1002\/ijc.25980","type":"journal-article","created":{"date-parts":[[2011,2,16]],"date-time":"2011-02-16T20:15:17Z","timestamp":1297887317000},"page":"105-112","source":"Crossref","is-referenced-by-count":51,"title":["Long\u2010term clinical and immunological effects of p53\u2010SLP\u00ae vaccine in patients with ovarian cancer"],"prefix":"10.1002","volume":"130","author":[{"given":"Ninke","family":"Leffers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee","family":"Vermeij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baukje\u2010Nynke","family":"Hoogeboom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute R.","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rinze","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ineke E.","family":"Hamming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ate G.","family":"van der Zee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kees J.","family":"Melief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sjoerd H.","family":"van der Burg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toos","family":"Daemen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans W.","family":"Nijman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,5,9]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24597"},{"key":"e_1_2_6_3_2","article-title":"Wild\u2010type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinoma","volume":"22","author":"Herrin V","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","unstructured":"HerrinVE AchtarMS SteinbergSM WhitesideTL WhitesideE WeickowskiE CzystowskaM VisusC BerzofskyJA KhleifSN. A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide\u2010pulsed dendritic cells in high risk ovarian cancer patients.Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings Part I. Vol 25 No. 18S (June 20 Supplement) 2007: 3011.","DOI":"10.1200\/jco.2007.25.18_suppl.3011"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0293-4"},{"key":"e_1_2_6_6_2","first-page":"1019","article-title":"Induction of p53\u2010specific immune responses in colorectal cancer patients receiving a recombinant ALVAC\u2010p53 candidate vaccine","volume":"8","author":"van der Burg SH","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2013"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-003-0493-5"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2003.12.010"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22710"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1880"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182070f17"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_2_6_14_2","first-page":"113","article-title":"Flow cytometric analysis of circulating dendritic cell subsets and intracellular cytokine production in advanced breast cancer patients","volume":"14","author":"Ferrari S","year":"2005","journal-title":"Oncol Rep"},{"key":"e_1_2_6_15_2","first-page":"11","volume-title":"Advances in carriers and adjuvants for veterinary biologics","author":"Kaeberle ML","year":"1986"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.25980","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.25980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T17:52:39Z","timestamp":1697478759000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.25980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,9]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1002\/ijc.25980"],"URL":"https:\/\/doi.org\/10.1002\/ijc.25980","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,9]]}}}